The Denver Tube Combined with Antiviral Drugs In the Treatment of HBV-related Cirrhosis with Refractory Ascites: A Report of Three Cases

• Main Authors: Wang Xiao-jin, Shi Li-qin, Fu Qing-chun, Ni Liu-da, Zhou Feng, Chen Jin-wei, Chen Cheng-wei
• Format: Article
• Language: English
• Published: Sciendo 2014-03-01
• Series: Infection International
• Subjects: Cirrhosis; decompensation; Ascites; Denver tube; Nucleos(t)ide analogue
• Online Access: http://www.degruyter.com/view/j/ii.2014.3.issue-1/ii-2017-0073/ii-2017-0073.xml?format=INT

Treatment of nucleos(t)ide antiviral drugs for decompensated HBV-related cirrhosis can significantly improve the prognosis. But those patients with refractory ascites possibly deteriorate due to the complications of ascites before any benefit from anti-viral drugs could be observed. Therefore, it is important to find a way to help the patients with HBV-related cirrhosis and refractory ascites to receive the full benefits from antiviral therapy. Peritoneovenous shunt (PVS) using Denver tube enables ascites to continuously bypass into systemic circulation, thereby reducing ascites and albumin input and improving quality of life. We report herein 3 cases of decompensated HBV-related cirrhosis with refractory ascites, PVS using Denver tube was combined with lamivudine for antiviral treatment before and after. Then, ascites was alleviated significantly or disapeared and viral responsed well. All patients achieved a satisfactory long-term survival from 6.7 to 14.7 years. It was suggested that the Denver shunt could be used as an adjuvant method to antiviral drugs for decompensated HBV-related cirrhosis with refractory ascites to help the patients reap the full benefits and maximize efficacy of antiviral treatment.